DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB)

DaTscan is first radiopharmaceutical diagnostic tracer approved by U.S. FDA for use in patients with suspected Dementia with Lewy Bodies (DLB) Builds on DaTscan market leadership globally with over one million doses already used around the world in the clinical evaluation of Parkinsonian syndromes  One in five patients with dementia suffers from DLB, the second... Read more

Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy

Announces $1.0 Billion Share Repurchase Program for Q4 2022 Separately Enters Into Agreement to Acquire The Binding Site Group WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today provided an update on capital deployment. Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a... Read more

Thermo Fisher Scientific to Acquire The Binding Site Group

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today... Read more